Edi Barkai, Prof.
Researcher
Claimed by owner 
MemoBoost
Former names:
Drug Treatment to Inhibit Dementia
MemoBoost
About
MemoBoost is developing a pioneering drug treatment designed to inhibit the onset of dementia. The companys technology is based on research into the scientific foundations of learning and memory in the brain.
MemoBoost is headed by Prof. Edi Barkai of the University of Haifas Sagol Department of Neurobiology and the head of the Laboratory for Neurobiology of Learning and Memory. Prof. Barkai is on the path to developing a cognitive/learning-enhancing drug that may counter the cognitive deficits suffered by dementia patients.
Prof. Barkais research has identified a specific receptor in the brain, in the mGluR family, which inhibits learning when its excitability is blocked and improves learning when its excitability is consistently enhanced. Using a research compound that activates this receptor, Prof. Barkais group has successfully shown that learning is significantly enhanced in a validated animal model of learning.
The compound is currently being modified and tested in order to develop a drug that will serve as a potent cognitive enhancer to tackle the onset of dementia and other cognitive deficits.
MemoBoost is headed by Prof. Edi Barkai of the University of Haifas Sagol Department of Neurobiology and the head of the Laboratory for Neurobiology of Learning and Memory. Prof. Barkai is on the path to developing a cognitive/learning-enhancing drug that may counter the cognitive deficits suffered by dementia patients.
Prof. Barkais research has identified a specific receptor in the brain, in the mGluR family, which inhibits learning when its excitability is blocked and improves learning when its excitability is consistently enhanced. Using a research compound that activates this receptor, Prof. Barkais group has successfully shown that learning is significantly enhanced in a validated animal model of learning.
The compound is currently being modified and tested in order to develop a drug that will serve as a potent cognitive enhancer to tackle the onset of dementia and other cognitive deficits.
Primary Sector
Life Sciences & HealthTech
Products
-
Geographic markets
Global
Funding
Total Funding
Undisclosed
Last Funding
Undisclosed
Funding Stage
Total Rounds
1
Investors
1
News
(0)The Team
(1)
EBP
Connect with
What is the reason for connecting?
Your company *
Your position *
Add invitation message
0/300
Sending invitation...
Company Lifecycle
Private Equity Funding
Seed
Undisclosed
Jun 2016
1 Investors
Undisclosed
Others
Academic Techonology
Mar 2016
undefined
New drug treatment approach to inhibit the onset of dementia
Media gallery
(1)Locations
Israel
Abba Khoushy Ave 199, Haifa, Israel
Locations
Israel
Abba Khoushy Ave 199, Haifa, Israel
Unlock financial data
Finder is provided for free by the non-profit organization Start-Up Nation Central.
- Get unlimited search results
- Save to custom lists - Smartlists
- Get notified with news and updates
- Connect with people
And much more...
I already have access,